Alexandria Real Estate Highlights Role in Blood Cancer Innovation
Alexandria Real Estate Equities (NYSE: ARE) is emphasizing its contributions to blood cancer research and treatment through strategic investments, tenant innovation, and philanthropy. The company supports tenants like Juno Therapeutics, known for pioneering CAR-T therapies such as Breyanzi® used in treating various lymphomas. Alexandria also partners with leading nonprofits including the Multiple Myeloma Research Foundation (MMRF) and National Marrow Donor Program to advance research and patient care. CEO Peter Moglia highlighted that blood cancers are a significant public health issue, with one diagnosis every three minutes and one death approximately every nine minutes in the U.S. Alexandria's long-term engagement includes funding for nonprofits focused on hematology and oncology, as well as employee volunteer initiatives like blood drives across its campuses. The company’s investments have included early-stage support of Juno Therapeutics through Alexandria Venture Investments before it was acquired by Celgene (now part of Bristol Myers Squibb). These efforts underscore Alexandria's role in fostering innovation within the life sciences sector.
Tickers: $ARE
Topics: Blood Cancer Research Healthcare Real Estate Investment Trusts (REITs)